(E/Z) -BCI

• Description:

  (E/Z) -BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z) -BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway[1].

• Product Name Alternative:

  NSC 150117

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H412

• Target:

  Apoptosis; Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/e-z-bci.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C\C4=CC=CC=C4

• Molecular Formula:

  C22H23NO

• Molecular Weight:

  317.42

• Precautions:

  P264-P270-P273-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

• References & Citations:

  [1]Zhang F, et al. DUSP6 Inhibitor (E/Z) -BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42 (2) :672-681.|[2]Wu QN, et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [15982-84-0]